<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67261">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02070939</url>
  </required_header>
  <id_info>
    <org_study_id>B7411001</org_study_id>
    <nct_id>NCT02070939</nct_id>
  </id_info>
  <brief_title>Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single-And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of PF- 06260414 In Healthy Western And Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single and multiple ascending dose study is the first evaluation of PF-0626414, a
      Selective Androgen Receptor Modulator in humans. The goal is to assess the safety,
      tolerability, pharmacokinetics and pharmacodynamics in healthy western and Japanese male
      subjects .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in 12-lead ECG parameters</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Quantitative changes in ECG intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (including total Hb and hematocrit), chemistry, fasting glucose, urinalysis</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour creatinine clearance (baseline and day 14).</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in total testosterone, free testosterone, estradiol, LH, FSH, SHBG.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in Prostate Specific Antigen (PSA).</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Dose: Cmax, Tmax, AUClast, AUCinf, CL/F, Vz/F, and t½,Cmax(dn), AUCinf(dn), AUClast(dn), t½.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: Cmax, Tmax Ctrough, C,av,AUC,CL/F, Vz/F, Rac , Rac,Cmax , PTR, Cmax(dn),AUCτ(dn), t½.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Pharmacokinetics: Amount of PF 06260414 excreted unchanged (AE and AE%), renal clearance (CLr).</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Dose: AUC(hormone or PSA), C0(hormone or PSA), Maximum PCB, Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effects of PF- 06260414 on sex hormones (total testosterone, free testosterone, estradiol, SHBG, LH and FSH) will be evaluated according to the scheduled timepoints in single ascending dose study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Dose: AUC(hormone or PSA), C0(hormone or PSA), Cmax(hormone or PSA), Cmin(hormone or PSA), Tmax(hormone or PSA), Tmin(hormone or PSA).</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SAD cohorts 1-6 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SAD Cohorts 1-6 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohorts 2-5 Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD cohorts 2-5 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese MAD cohort 7 Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese MAD cohort 7 Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06260414</intervention_name>
    <description>Subjects will receive single doses of 1,3,10,30,100,200 mg of PF-06260414 (solution) in a dose escalating format</description>
    <arm_group_label>SAD cohorts 1-6 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format</description>
    <arm_group_label>SAD Cohorts 1-6 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06260414</intervention_name>
    <description>Subjects will receive PF-06260414 doses (solution) twice daily for 14 days</description>
    <arm_group_label>MAD cohorts 2-5 Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive PF-06260414 matching placebo doses (solution) twice daily for 14 days</description>
    <arm_group_label>MAD cohorts 2-5 Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06260414</intervention_name>
    <description>Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days</description>
    <arm_group_label>Japanese MAD cohort 7 Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days</description>
    <arm_group_label>Japanese MAD cohort 7 Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no
             clinically relevant abnormalities identified by a detailed medical history, full
             physical examination, including blood pressure and pulse rate measurement, 12 lead
             ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110
             lbs).

          -  Additional inclusion criteria for subjects to be enrolled in Japanese cohort only:
             Japanese subjects who have four Japanese grandparents born in Japan.

        Exclusion Criteria:

          -  Serum total testosterone level &lt;270 or &gt;1070 ng/dL

          -  Serum Prostate Specific Antigen (PSA) level &gt;4 ng/mL.

          -  Hematocrit &gt;48%.

          -  eGFR &gt;150 ml/min/1.73m2.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7411001&amp;StudyName=Study%20To%20Evaluate%20Safety%20And%20Tolerability%20Of%20Single%20And%20Multiple%20Ascending%20Doses%20Of%20PF-%2006260414%20In%20Healthy%20Western%20And%20Japanese%20Male%</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>February 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Randomized</keyword>
  <keyword>Double Blind</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Single and Multiple Dose Escalation</keyword>
  <keyword>Safety Tolerability</keyword>
  <keyword>PK</keyword>
  <keyword>PD</keyword>
  <keyword>PF-06460414</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
